134 related articles for article (PubMed ID: 9879813)
1. Mechanistic study on liver tumor promoting effects of piperonyl butoxide in rats.
Okamiya H; Mitsumori K; Onodera H; Ito S; Imazawa T; Yasuhara K; Takahashi M
Arch Toxicol; 1998 Nov; 72(11):744-50. PubMed ID: 9879813
[TBL] [Abstract][Full Text] [Related]
2. Piperonyl butoxide induces hepatocellular carcinoma in male CD-1 mice.
Takahashi O; Oishi S; Fujitani T; Tanaka T; Yoneyama M
Arch Toxicol; 1994; 68(7):467-9. PubMed ID: 7979964
[TBL] [Abstract][Full Text] [Related]
3. Chronic toxicity studies of piperonyl butoxide in F344 rats: induction of hepatocellular carcinoma.
Takahashi O; Oishi S; Fujitani T; Tanaka T; Yoneyama M
Fundam Appl Toxicol; 1994 Feb; 22(2):293-303. PubMed ID: 7911767
[TBL] [Abstract][Full Text] [Related]
4. Chronic toxicity studies of piperonyl butoxide in CD-1 mice: induction of hepatocellular carcinoma.
Takahashi O; Oishi S; Fujitani T; Tanaka T; Yoneyama M
Toxicology; 1997 Dec; 124(2):95-103. PubMed ID: 9457999
[TBL] [Abstract][Full Text] [Related]
5. Effect of piperonyl butoxide on cell replication and xenobiotic metabolism in the livers of CD-1 mice and F344 rats.
Phillips JC; Price RJ; Cunninghame ME; Osimitz TG; Cockburn A; Gabriel KL; Preiss FJ; Butler WH; Lake BG
Fundam Appl Toxicol; 1997 Jul; 38(1):64-74. PubMed ID: 9268606
[TBL] [Abstract][Full Text] [Related]
6. Subacute toxicity of piperonyl butoxide in ICR mice.
Fujitani T; Tanaka T; Hashimoto Y; Yoneyama M
Toxicology; 1993 Oct; 83(1-3):93-100. PubMed ID: 8248953
[TBL] [Abstract][Full Text] [Related]
7. Sub-acute toxicity of piperonyl butoxide in F344 rats.
Fujitani T; Ando H; Fujitani K; Ikeda T; Kojima A; Kubo Y; Ogata A; Oishi S; Takahashi H; Takahashi O
Toxicology; 1992; 72(3):291-8. PubMed ID: 1585383
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathological analysis for determining the possible mechanism of piperonyl butoxide-induced hepatocarcinogenesis in mice.
Muguruma M; Nishimura J; Jin M; Kashida Y; Moto M; Takahashi M; Yokouchi Y; Mitsumori K
Toxicology; 2006 Dec; 228(2-3):178-87. PubMed ID: 17014948
[TBL] [Abstract][Full Text] [Related]
9. Piperonyl butoxide: Mode of action analysis for mouse liver tumour formation and human relevance.
Lake BG; Price RJ; Scott MP; Chatham LR; Vardy A; Osimitz TG
Toxicology; 2020 Jun; 439():152465. PubMed ID: 32320717
[TBL] [Abstract][Full Text] [Related]
10. Different pathways of constitutive androstane receptor-mediated liver hypertrophy and hepatocarcinogenesis in mice treated with piperonyl butoxide or decabromodiphenyl ether.
Sakamoto Y; Inoue K; Takahashi M; Taketa Y; Kodama Y; Nemoto K; Degawa M; Gamou T; Ozawa S; Nishikawa A; Yoshida M
Toxicol Pathol; 2013; 41(8):1078-92. PubMed ID: 23531792
[TBL] [Abstract][Full Text] [Related]
11. Threshold dose of piperonyl butoxide that induces reactive oxygen species-mediated hepatocarcinogenesis in rats.
Muguruma M; Kawai M; Dewa Y; Nishimura J; Saegusa Y; Yasuno H; Jin M; Matsumoto S; Takabatake M; Arai K; Mitsumori K
Arch Toxicol; 2009 Feb; 83(2):183-93. PubMed ID: 18648771
[TBL] [Abstract][Full Text] [Related]
12. The relationship between decrease in Cx32 and induction of P450 isozymes in the early phase of clofibrate hepatocarcinogenesis in the rat.
Shoda T; Mitsumori K; Onodera H; Toyoda K; Uneyama C; Imazawa T; Hirose M
Arch Toxicol; 1999 Sep; 73(7):373-80. PubMed ID: 10550479
[TBL] [Abstract][Full Text] [Related]
13. Estrogen and androgen receptor status in hepatocellular hypertrophy induced by phenobarbital, clofibrate, and piperonyl butoxide in F344 rats.
Fujimoto N; Inoue K; Yoshida M; Nishikawa A; Ozawa S; Gamou T; Nemoto K; Degawa M
J Toxicol Sci; 2012; 37(2):281-6. PubMed ID: 22467018
[TBL] [Abstract][Full Text] [Related]
14. Oncogenicity studies of piperonyl butoxide in rats and mice.
Butler WH; Gabriel KL; Osimitz TG; Preiss FJ
Hum Exp Toxicol; 1998 Jun; 17(6):323-30. PubMed ID: 9688356
[TBL] [Abstract][Full Text] [Related]
15. Liver tumor-promoting effect of beta-naphthoflavone, a strong CYP 1A1/2 inducer, and the relationship between CYP 1A1/2 induction and Cx32 decrease in its hepatocarcinogenesis in the rat.
Shoda T; Mitsumori K; Onodera H; Toyoda K; Uneyama C; Takada K; Hirose M
Toxicol Pathol; 2000; 28(4):540-7. PubMed ID: 10930040
[TBL] [Abstract][Full Text] [Related]
16. Global DNA methylation screening of liver in piperonyl butoxide-treated mice in a two-stage hepatocarcinogenesis model.
Yafune A; Kawai M; Itahashi M; Kimura M; Nakane F; Mitsumori K; Shibutani M
Toxicol Lett; 2013 Oct; 222(3):295-302. PubMed ID: 23968726
[TBL] [Abstract][Full Text] [Related]
17. Hepatotoxicity of piperonyl butoxide in male F344 rats.
Fujitani T; Tada Y; Yoneyama M
Toxicology; 1993 Nov; 84(1-3):171-83. PubMed ID: 8266336
[TBL] [Abstract][Full Text] [Related]
18. Carcinogenesis bioassay of technical-grade piperonyl butoxide in F344 rats.
Cardy RH; Renne RA; Warner JW; Cypher RL
J Natl Cancer Inst; 1979 Mar; 62(3):569-78. PubMed ID: 283286
[TBL] [Abstract][Full Text] [Related]
19. Suppressive effect of liver tumor-promoting activities in rats subjected to combined administration of phenobarbital and piperonyl butoxide.
Morita R; Yafune A; Shiraki A; Itahashi M; Akane H; Nakane F; Suzuki K; Shibutani M; Mitsumori K
J Toxicol Sci; 2013; 38(5):679-88. PubMed ID: 24025784
[TBL] [Abstract][Full Text] [Related]
20. Possible involvement of oxidative stress in piperonyl butoxide induced hepatocarcinogenesis in rats.
Muguruma M; Unami A; Kanki M; Kuroiwa Y; Nishimura J; Dewa Y; Umemura T; Oishi Y; Mitsumori K
Toxicology; 2007 Jul; 236(1-2):61-75. PubMed ID: 17498859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
